Navigation Links
Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic
Date:6/2/2011

BOULDER, Colo., and PLEASANTON, Calif., June 2, 2011 /PRNewswire/ -- Clovis Oncology, Inc. and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that they have entered into an agreement to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test. The goal is to identify activating epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC), including the EGFR T790M mutation.  

"Once again we are able to demonstrate Roche's expertise in Personalized Healthcare. Our agreement with Clovis Oncology strengthens our position as the partner of choice for the development of companion diagnostics. Roche hopes that through this collaboration we will be able to advance oncology diagnostic testing and drug therapy for the benefit of many patients world-wide," said Paul Brown, Head of Roche Molecular Diagnostics.

Patrick Mahaffy, President and CEO, Clovis Oncology added: "We are very pleased to partner with Roche, a clear leader in the development, manufacturing and marketing of companion diagnostic tools.  By incorporating a companion diagnostic during clinical and commercial development of CO-1686, we reinforce our commitment to focus development programs on specific subsets of cancer populations that are most likely to benefit from our targeted therapies."

About CO-1686

CO-1686 is currently in pre-clinical development for advanced NSCLC patients.  CO-1686 has been designed to target and covalently bind to the activating and T790M mutant forms of EGFR.  It does so while also sparing wild-type (normal) EGFR and may thus treat refractory NSCLC while minimizing dose-limiting side effects.   CO-1686 was licensed to Clovis Oncology from Avila Therapeutics, Inc.

About the cobas 4800 system

The cobas EGFR mutation assay will run on the Roche cobas 4800 System, a platform designed to deliver new standards in laboratory testing efficiency and medically relevant diagnostic information.  Cobas 4800 was recently approved in the US and all countries accepting a CE mark for use with the HPV test.

About Clovis Oncology, Inc.

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis intends to target development programs at specific subsets of cancer populations, and will simultaneously develop diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. The Company is headquartered in Boulder, Colorado, and has additional offices and laboratories in San Francisco and Cambridge, England.  For more information about Clovis Oncology, please visit the Company's website at www.clovisoncology.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

For Clovis Oncology
Anna Sussman / Breanna Burkart
Scout Investor Relations
+1 303 907 5358 or +1 303 907 5162
anna@scoutir.com or breanna@scoutir.com

For Roche
Media Hotline 888-545-2443

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Clovis Oncology, Inc.; Roche Molecular Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Florida Hospital First U.S. Site to Adopt New Automated Laboratory Solution From Roche
2. Roche Symposium Showcases Accomplishments of Next Generation of Chemists
3. Roche Submits Application for Clearance of Chlamydia and Gonorrhoeae Test
4. Rochester Medical Reports Second Quarter Results
5. Rochester Medical Announces Second Quarter 2011 Earnings Conference Call Thursday, May 5, 2011
6. Roche Launches EMR Interface for VA to Facilitate Diabetes Management
7. Rochester Medical Completes Acquisition of Laprolan
8. MITs Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research
9. Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
10. Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
11. Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):